LoginRegister
    Novartis sees 2019 growth as it sheds eyecare unit, narrows focusNovartis sees 2019 growth as it sheds eyecare unit, narrows focus
    Incorrect Brand: Chemist slapped of Rs 1.15 lakh for providing alternative to prescribed drugIncorrect Brand: Chemist slapped of Rs 1.15 lakh for providing alternative to prescribed drug
    Cipla gets USFDA nod for Medroxyprogesterone injectableCipla gets USFDA nod for Medroxyprogesterone injectable
    Dr. Reddys gets USFDA approval for TOSYMRA for treatment of migraineDr. Reddy's gets USFDA approval for TOSYMRA for treatment of migraine
    Zydus Wellness to sell shares worth Rs 2575 crore to Cadilla and three othersZydus Wellness to sell shares worth Rs 2575 crore to Cadilla and three others
    Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes AmgenExclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen
    Manufacturer to pay penalty for entire batch if single drug found substandard: Govt New ProposalManufacturer to pay penalty for entire batch if single drug found substandard: Govt New Proposal
    Lupin gets 6 observations from USFDA for its Pithampur Unit-2Lupin gets 6 observations from USFDA for its Pithampur Unit-2
    Price Ceiling, Compulsory licensing of patented medicines Necessary: Govt panelPrice Ceiling, Compulsory licensing of patented medicines Necessary: Govt panel
    Aurobindo recalls nearly 5 lakh bottles of blood pressure drug in USAurobindo recalls nearly 5 lakh bottles of blood pressure drug in US
    Glenmark Pharma gets tentative ANDA approval for Topiramate Extended-Release CapsulesGlenmark Pharma gets tentative ANDA approval for Topiramate Extended-Release Capsules
    DOP directs NPPA to refix the ceiling price of Gentamicin based on Abbot applicationDOP directs NPPA to refix the ceiling price of Gentamicin based on Abbot application
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X